MedTrace Logo

Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas

NCT01161862 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-11-14

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that our closed-loop glucose-control system can provide BG control in subjects with type 1 diabetes using the estimated BG signal from a CGM as the input signal to the controller.

Conditions

Interventions

DEVICE

Bi-hormonal (insulin and glucagon) artificial pancreas

Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump

Sponsors & Collaborators

  • Massachusetts General Hospital

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Juvenile Diabetes Research Foundation

    collaborator OTHER

  • The Leona M. and Harry B. Helmsley Charitable Trust

    collaborator OTHER

  • Boston University Charles River Campus

    lead OTHER

Principal Investigators

  • Steven J Russell, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-12-31
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01161862 on ClinicalTrials.gov